eligibility_summary
Adults with measurable, histologically confirmed relapsed/refractory follicular lymphoma (grade 1–3a), ECOG 0–1. Must have 1–3 prior systemic lines incl anti‑CD20 plus an alkylating agent, if only 1 prior line, must have high‑risk features. Disease must have recurred or been refractory. Exclude cardiac history, bleeding disorders, or CNS/brain involvement. Other protocol criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized trial in relapsed/refractory follicular lymphoma comparing lisocabtagene maraleucel (liso-cel) vs standard regimens (R-CHOP, B-R, or R²). Liso-cel: autologous CD19-directed CAR T-cell therapy (genetically modified T cells) given after fludarabine, mechanism: CAR-mediated recognition and cytotoxic killing of CD19+ B-cell lymphoma. SOC agents: rituximab (anti-CD20 monoclonal antibody, ADCC/complement B-cell depletion), cyclophosphamide and bendamustine (alkylators, DNA crosslinks), doxorubicin (anthracycline/topoisomerase II inhibitor), vincristine (vinca alkaloid, microtubule inhibitor), prednisone (glucocorticoid, lympholytic), lenalidomide (IMiD, cereblon-mediated IKZF1/3 degradation, boosts T/NK activity). Targets/pathways: CD19+ and CD20+ B cells, DNA damage pathways, microtubules, and immune effector activation. Primary endpoint: PFS.